title: Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma.
abstract: We have shown that boron neutron capture therapy (BNCT) could be an alternative for the treatment of poorly differentiated thyroid carcinoma (PDTC). Histone deacetylase inhibitors (HDACI) like sodium butyrate (NaB) cause hyperacetylation of histone proteins and show capacity to increase the gamma irradiation effect. The purpose of these studies was to investigate the use of the NaB as a radiosensitizer of the BNCT for PDTC. Follicular thyroid carcinoma cells (WRO) and rat thyroid epithelial cells (FRTL-5) were incubated with 1 mM NaB and then treated with boronophenylalanine ¹⁰BPA (10 μg ¹⁰B ml⁻¹) + neutrons, or with 2, 4-bis (α,β-dihydroxyethyl)-deutero-porphyrin IX ¹⁰BOPP (10 μg ¹⁰B ml⁻¹) + neutrons, or with a neutron beam alone. The cells were irradiated in the thermal column facility of the RA-3 reactor (flux = (1.0 ± 0.1) × 10¹⁰ n cm⁻² s⁻¹). Cell survival decreased as a function of the physical absorbed dose in both cell lines. Moreover, the addition of NaB decreased cell survival (p < 0.05) in WRO cells incubated with both boron compounds. NaB increased the percentage of necrotic and apoptotic cells in both BNCT groups (p < 0.05). An accumulation of cells in G2/M phase at 24 h was observed for all the irradiated groups and the addition of NaB increased this percentage. Biodistribution studies of BPA (350 mg kg⁻¹ body weight) 24 h after NaB injection were performed. The in vivo studies showed that NaB treatment increases the amount of boron in the tumor at 2-h post-BPA injection (p < 0.01). We conclude that NaB could be used as a radiosensitizer for the treatment of thyroid carcinoma by BNCT.
authors: Department of Radiobiology, National Atomic Energy Commission-CNEA, Avenida General Paz 1499, San Martín 1650, Buenos Aires, Argentina.
authors: M
authors: M
authors: Perona
authors: C
authors: C
authors: Rodríguez
authors: M
authors: M
authors: Carpano
authors: L
authors: L
authors: Thomasz
authors: S
authors: S
authors: Nievas
authors: M
authors: M
authors: Olivera
authors: S
authors: S
authors: Thorp
authors: P
authors: P
authors: Curotto
authors: E
authors: E
authors: Pozzi
authors: S
authors: S
authors: Kahl
authors: M
authors: M
authors: Pisarev
authors: G
authors: G
authors: Juvenal
authors: A
authors: A
authors: Dagrosa
mesh_terms: D000107:Acetylation; D000818:Animals; D001896:Boron Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics; D016754:Boron Neutron Capture Therapy; D020148:Butyric Acid / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage*; D006657:Histones / Q000378:metabolism; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D010649:Phenylalanine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D011829:Radiation Dosage; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy*
chemical_list: D001896:Boron Compounds; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D011838:Radiation-Sensitizing Agents; D020148:Butyric Acid; D010649:Phenylalanine; C033685:4-boronophenylalanine
references: Endocrinol Metab Clin North Am. 2008 Jun;37(2):497-509, xi
references: 18502339
references: Cancer Res. 2000 Oct 15;60(20):5781-8
references: 11059774
references: Duodecim. 2011;127(16):1697-703
references: 21972588
references: Radiat Res. 2004 Jun;161(6):667-74
references: 15161353
references: Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8
references: 15637150
references: Endocrinology. 2005 Sep;146(9):3967-74
references: 15919754
references: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10833-8
references: 11535817
references: World J Surg Oncol. 2009 May 21;7:49
references: 19460134
references: Cancer Genet Cytogenet. 2010 Jan 15;196(2):124-32
references: 20082847
references: Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S226-9
references: 19406651
references: Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14639-44
references: 20679231
references: Biochem Cell Biol. 2003 Jun;81(3):123-9
references: 12897845
references: Cancer Res. 2009 Mar 1;69(5):2126-32
references: 19244126
references: Nat Rev Cancer. 2006 Jan;6(1):38-51
references: 16397526
references: Oncogene. 1999 Nov 25;18(50):7016-25
references: 10597302
references: Arq Bras Endocrinol Metabol. 2007 Jul;51(5):852-6
references: 17891250
references: BMC Mol Biol. 2010 Jun 24;11:49
references: 20576112
references: Cancer Res. 2004 Apr 1;64(7):2590-600
references: 15059916
references: Nat Rev Cancer. 2001 Dec;1(3):194-202
references: 11902574
references: Clin Cancer Res. 2001 Apr;7(4):962-70
references: 11309347
references: Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9
references: 10954755
references: Clin Cancer Res. 2005 Jul 1;11(13):4912-22
references: 16000590
references: Mol Cancer. 2008 Jun 12;7:55
references: 18549473
references: Radiat Res. 1988 Apr;114(1):186-91
references: 3353504
references: Mol Cancer Res. 2007 Oct;5(10):981-9
references: 17951399
references: Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1059-66
references: 17967301
references: Radiat Res. 1985 Dec;104(3):443-8
references: 4080986
references: Mol Biol Cell. 2000 Jun;11(6):2069-83
references: 10848630
references: Oncogene. 2007 Aug 13;26(37):5541-52
references: 17694093
references: Appl Radiat Isot. 2011 Dec;69(12):1823-5
references: 21684170
references: Int J Cancer. 2005 Apr 10;114(3):380-6
references: 15578701